E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 11 940 KRW 0.59%
Market Cap: 436.2B KRW
Have any thoughts about
EuBiologics Co Ltd?
Write Note
EuBiologics Co Ltd
/
Balance Sheet
/
Note Receivable

EuBiologics Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

EuBiologics Co Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
E
EuBiologics Co Ltd
KOSDAQ:206650
Note Receivable
₩782m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Note Receivable
₩78.2B
CAGR 3-Years
82%
CAGR 5-Years
48%
CAGR 10-Years
21%
SK Bioscience Co Ltd
KRX:302440
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Note Receivable
₩827.5m
CAGR 3-Years
39%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Note Receivable
₩3B
CAGR 3-Years
-18%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

EuBiologics Co Ltd
Glance View

Market Cap
435.3B KRW
Industry
Biotechnology

EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Intrinsic Value
17 631.48 KRW
Undervaluation 32%
Intrinsic Value
Price
E
What is Intrinsic Value?

See Also

What is EuBiologics Co Ltd's Note Receivable?
Note Receivable
782m KRW

Based on the financial report for Sep 30, 2024, EuBiologics Co Ltd's Note Receivable amounts to 782m KRW.

What is EuBiologics Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
29%

The average annual Note Receivable growth rates for EuBiologics Co Ltd have been 29% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.